Last updated: February 19, 2026
AZD1390 is an investigational Aurora kinase inhibitor developed by AstraZeneca, targeting multiple Aurora kinase family members (A, B, and C) for oncological applications. Clinical trials are ongoing, with initial data suggesting potential efficacy in specific cancer types, particularly those with dysregulated Aurora kinase activity. The market for targeted oncology therapies remains robust, with Aurora kinase inhibitors representing a promising area for addressing unmet medical needs.
What is the current development status of AZD1390?
AZD1390 is currently in clinical development. The drug is being evaluated in several Phase I and Phase II trials across various solid tumor indications.
- Phase I Studies: These trials are designed to assess the safety, tolerability, and pharmacokinetics of AZD1390, as well as to determine the recommended Phase II dose.
- A Phase I study (NCT03575159) investigated AZD1390 as a monotherapy in patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and other malignancies. The study enrolled 160 participants [1].
- Another Phase I trial (NCT04596678) is evaluating AZD1390 in combination with olaparib in patients with platinum-resistant ovarian cancer and other solid tumors. This study is ongoing [2].
- Phase II Studies: These trials aim to evaluate the efficacy of AZD1390 in specific cancer types.
- A Phase II study (NCT04718094) is assessing AZD1390 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed on or after platinum-based chemotherapy. Enrollment targets 130 patients [3].
- Another Phase II trial (NCT05047601) is investigating AZD1390 in patients with advanced solid tumors that have progressed after treatment with an Aurora kinase inhibitor. This trial also includes patients with known BRCA1/2 mutations or deleterious germline mutations in homologous recombination repair (HRR) genes [4].
What are the key scientific principles behind AZD1390's mechanism of action?
AZD1390 is designed to inhibit Aurora kinases, a family of serine/threonine kinases crucial for regulating cell division (mitosis).
- Aurora Kinase Family: The Aurora kinase family comprises three main members:
- Aurora A: Primarily involved in centrosome maturation and separation, and mitotic spindle assembly. Overexpression is associated with aneuploidy and tumor progression [5].
- Aurora B: A component of the chromosomal passenger complex, essential for chromosome condensation, spindle assembly, and cytokinesis (cell division) [5].
- Aurora C: Primarily expressed in germ cells, but its role in somatic cell cancer is less defined [5].
- Mechanism of Inhibition: AZD1390 acts as a potent inhibitor of Aurora A and Aurora B kinases. By inhibiting these enzymes, AZD1390 disrupts the proper progression of mitosis, leading to:
- Mitotic Arrest: Cells are prevented from completing mitosis.
- Aneuploidy: Chromosome segregation errors can lead to an abnormal number of chromosomes.
- Apoptosis: Ultimately, these cellular disruptions trigger programmed cell death in cancer cells [6].
- Therapeutic Rationale: Cancer cells often exhibit higher expression and activity of Aurora kinases compared to normal cells. This makes Aurora kinases attractive targets for cancer therapy. Inhibiting these kinases selectively targets rapidly dividing cancer cells, potentially leading to a therapeutic effect with manageable toxicity [6].
Which specific cancer types are being investigated for AZD1390 treatment?
Clinical trials are exploring AZD1390's potential in a range of solid tumors.
- Non-Small Cell Lung Cancer (NSCLC): Included in Phase I evaluations.
- Small Cell Lung Cancer (SCLC): Included in Phase I evaluations.
- Head and Neck Squamous Cell Carcinoma (HNSCC): Being investigated in combination with pembrolizumab in a Phase II trial for recurrent or metastatic disease after platinum-based chemotherapy [3].
- Ovarian Cancer: Investigated in combination with olaparib in a Phase I trial for platinum-resistant disease [2].
- General Advanced Solid Tumors: AZD1390 is being evaluated as a monotherapy and in combination with other agents in broader populations of patients with advanced or refractory solid tumors [1, 4].
What is the competitive landscape for Aurora kinase inhibitors?
The Aurora kinase inhibitor landscape includes both approved therapies and a number of drugs in various stages of clinical development.
- Approved Therapies: As of the latest available data, there are no approved Aurora kinase inhibitors as monotherapies in major markets like the US or EU. However, the field is actively developing.
- Key Competitors in Development: Several companies have Aurora kinase inhibitors in their pipelines. While specific details on their target selectivity and stage of development can vary, some notable examples include:
- Alisertib (MLN8237): Developed by Takeda, this Aurora A inhibitor has been investigated in various hematological malignancies and solid tumors, including lymphomas and NSCLC. It has shown activity but has also faced challenges with toxicity [7].
- Barasertib (AZD2811): Also from AstraZeneca, this is a selective Aurora B kinase inhibitor that has been evaluated in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [8].
- Danopertimod (HMN-214): Developed by Jiangsu Hengrui Medicine, this pan-Aurora inhibitor has been explored in solid tumors.
- Filanesib (ARRY-501): Formerly developed by Arrygen, it targets Aurora A and has been investigated in various solid tumors [9].
- Combination Strategies: A significant trend is the investigation of Aurora kinase inhibitors in combination therapies, particularly with chemotherapy, targeted agents (like PARP inhibitors), and immunotherapies. This approach aims to enhance efficacy and overcome resistance mechanisms. AZD1390's evaluation with olaparib and pembrolizumab exemplifies this strategy.
What are the projected market opportunities for AZD1390?
The market potential for AZD1390 is tied to its demonstrated efficacy and safety in specific indications, its potential for combination therapy, and the overall growth of the precision oncology market.
- Targeted Oncology Market Growth: The global oncology market is projected to continue its substantial growth, driven by advancements in targeted therapies, immunotherapies, and diagnostics. Forecasts indicate a market value exceeding $400 billion by 2030 [10].
- Unmet Needs in Investigated Indications:
- Head and Neck Cancer: Recurrent or metastatic HNSCC, particularly after platinum-based chemotherapy, represents a significant unmet need, with limited effective treatment options [11]. Success in combination with pembrolizumab could position AZD1390 strongly in this segment.
- Ovarian Cancer: Platinum-resistant ovarian cancer also has a substantial unmet need. Combination with olaparib, a PARP inhibitor, is a rational approach given the potential for synthetic lethality in BRCA-mutated tumors [12].
- Potential for Biomarker-Driven Therapy: If AZD1390 shows differential efficacy in tumors with specific biomarkers (e.g., high Aurora kinase expression, certain genetic alterations), its market penetration could be enhanced through precision medicine approaches.
- Competitive Differentiation: The success of AZD1390 will depend on its ability to demonstrate superior efficacy, a more favorable safety profile, or synergistic activity in combination therapies compared to existing and emerging Aurora kinase inhibitors. Its broad spectrum inhibition (Aurora A and B) may offer advantages in certain contexts.
- Estimated Market Size: Quantifying the precise market size for AZD1390 is speculative without advanced clinical data and regulatory approval. However, considering the patient populations in indications like HNSCC and ovarian cancer, and the premium pricing typical for novel oncology agents, the addressable market could range from hundreds of millions to over a billion dollars annually, depending on the number of approved indications and market penetration.
What are the challenges and risks associated with AZD1390 development?
Several challenges and risks are inherent in the development of any novel oncology drug, including AZD1390.
- Clinical Trial Failure: The primary risk is the failure to demonstrate statistically significant efficacy or an acceptable safety profile in late-stage clinical trials. This can occur due to lack of therapeutic benefit, unacceptable toxicity, or poor patient outcomes compared to standard of care or investigational comparators.
- Toxicity Profile: Aurora kinase inhibitors, by their nature of targeting cell division, can have dose-limiting toxicities affecting rapidly dividing normal tissues (e.g., bone marrow suppression, gastrointestinal issues). Managing and mitigating these toxicities is crucial for successful development and widespread clinical adoption. Early Phase I data on AZD1390's safety and tolerability will be critical.
- Competitive Pressures: The Aurora kinase inhibitor space is competitive. Other drugs in development or those that gain approval earlier could capture market share. The efficacy and safety profile of AZD1390 will be benchmarked against these competitors.
- Regulatory Hurdles: Obtaining regulatory approval from agencies like the FDA and EMA requires robust data demonstrating safety and efficacy. Complex trial designs, manufacturing quality issues, or post-market surveillance concerns can delay or prevent approval.
- Biomarker Identification and Validation: Identifying reliable biomarkers to predict patient response to AZD1390 is essential for its successful positioning as a targeted therapy. Without clear biomarkers, patient selection may be broad, potentially diluting efficacy signals and increasing trial complexity.
- Combination Therapy Complexity: While combination therapies offer potential benefits, they also introduce complexities in trial design, drug-drug interactions, and managing overlapping toxicities. Demonstrating the added benefit of AZD1390 in combination regimens is critical.
Key Takeaways
- AZD1390 is an AstraZeneca-developed Aurora kinase inhibitor (Aurora A and B) in Phase I/II clinical trials for various solid tumors, including HNSCC and ovarian cancer.
- Its mechanism targets mitotic disruption, inducing cell cycle arrest and apoptosis in cancer cells, leveraging the often-elevated Aurora kinase activity in tumors.
- Current clinical development focuses on monotherapy and combination strategies with agents like pembrolizumab and olaparib.
- The competitive landscape for Aurora kinase inhibitors is active, with multiple molecules in development and a trend towards combination approaches.
- Market projections for AZD1390 are contingent on successful clinical outcomes, demonstrating clear efficacy and safety advantages in specific, high-unmet-need indications within the expanding precision oncology market.
- Key development challenges include demonstrating clinical efficacy, managing toxicity, navigating regulatory approvals, and differentiating from a competitive pipeline.
Frequently Asked Questions
-
What is the primary difference between AZD1390 and other Aurora kinase inhibitors in development?
AZD1390 is designed as a potent inhibitor of both Aurora A and Aurora B kinases, offering a dual mechanism of action. The specific selectivity profile and resulting in vivo activity relative to other Aurora kinase inhibitors will be a key differentiator if clinical data supports this.
-
Are there any specific genetic mutations or biomarkers that are being targeted or evaluated for AZD1390 responsiveness?
While not exclusively limited to specific mutations, AZD1390 is being evaluated in patients with tumors that have shown dysregulated Aurora kinase activity, or in combinations where biomarkers are relevant (e.g., BRCA mutations for olaparib combination). Further research is likely exploring genetic signatures associated with sensitivity.
-
What is the typical route of administration for AZD1390?
Based on early-phase study designs, AZD1390 is administered orally.
-
When is AZD1390 expected to complete its ongoing clinical trials?
Completion dates for ongoing clinical trials can vary and are subject to change based on recruitment rates, data analysis, and regulatory timelines. For specific trial timelines, reference to clinical trial registries like ClinicalTrials.gov is recommended.
-
What is the potential for AZD1390 in hematological malignancies, given the role of Aurora kinases in cell division?
While current development appears focused on solid tumors, Aurora kinases are also implicated in hematological malignancies. Previous Aurora kinase inhibitors have been investigated in these settings (e.g., AZD2811 in AML/MDS). Future exploration of AZD1390 in hematological cancers is a possibility, pending results from its solid tumor studies.
Cited Sources
[1] AstraZeneca. (n.d.). A Study of AZD1390 in Participants With Advanced Solid Tumors. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03575159
[2] AstraZeneca. (n.d.). A Study of AZD1390 in Combination With Olaparib in Participants With Platinum-Resistant Ovarian Cancer and Other Solid Tumors. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04596678
[3] AstraZeneca. (n.d.). AZD1390 Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04718094
[4] AstraZeneca. (n.d.). A Study of AZD1390 in Participants With Advanced Solid Tumors That Have Progressed Following Treatment With an Aurora Kinase Inhibitor. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT05047601
[5] Fu, J., Bian, X., Yu, S., Wu, X., Hu, Y., Chen, H., & Wang, J. (2020). Aurora Kinase Inhibitors in Cancer Therapy. Frontiers in Oncology, 10, 1639. https://doi.org/10.3389/fonc.2020.01639
[6] Han, Y., & Xu, S. (2021). Aurora Kinase Inhibitors: A New Generation of Cancer Therapy. Journal of Oncology, 2021, 5589342. https://doi.org/10.1155/2021/5589342
[7] Paoletti, X., Spano, J. P., Le Rolland, A., Lacroix, L., Lapeyre, A. B., Faivre, S., ... & Veronese, L. D. (2017). Phase I study of alisertib (MLN8237), an Aurora A kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 35(3), 339-348. https://doi.org/10.1007/s10637-017-0448-1
[8] Smith, B. D., Wang, E. S., Uy, G. L., Zeidan, A. M., Walter, R. B., Dina, R. E., ... & DeAngelo, D. J. (2021). Barasertib, an Aurora B kinase inhibitor, combined with azacitidine in patients with newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma, 62(3), 570-582. https://doi.org/10.1080/10428194.2020.1843289
[9] ClinicalTrials.gov. (n.d.). Filanesib (ARRY-501) in Patients With Advanced Solid Tumors. Retrieved from https://clinicaltrials.gov/ct2/show/NCT00572734
[10] Grand View Research. (2023, October). Oncology Drugs Market Size, Share & Trends Analysis Report By Drug Type, By Cancer Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/oncology-drugs-market
[11] Marur, S., & Ferris, R. L. (2018). The Changing Landscape of Head and Neck Cancer Therapeutics. JAMA Oncology, 4(6), 868-870. https://doi.org/10.1001/jamaoncol.2018.0719
[12] Colombo, N., Brozzi, A., Sismondi, P., Crapanzano, P., Sartori, E., Marchetti, C., ... & Pignata, S. (2021). Poly(ADP-ribose) polymerase inhibitors in ovarian cancer. Expert Review of Anticancer Therapy, 21(8), 827-841. https://doi.org/10.1080/14737140.2021.1938587
